Juliana Ianus

TL;DR: In participants with atrial fibrillation undergoing PCI with placement of stents, the administration of either low-dose rivaroxaban plus a P2Y12 inhibitor for 12 months or very-low-dose thrombolysis in Myocardial Infarction plus DAPT for 1, 6, or 12 months was associated with a lower rate of clinically significant bleeding.

TL;DR: In the CANVAS Program, the most common reasons for hospitalization were cardiac disorders, infections and infestations, and nervous system disorders as discussed by the authors, and there was no significant difference between the canagliflozin and placebo groups in the rates of total hospitalizations due to infection and infostations (RR 0.92; 95% confidence interval [CI] 0.86, 0.88).

TL;DR: SmartADHERE as mentioned in this paper was a randomized trial that tested a personalized digital and human direct oral anticoagulant adherence intervention compared to usual care, which consisted of combination of a medication management smartphone app, daily app-based reminders, adaptive text messaging, and phone-based counseling for severe non-adherence.

TL;DR: In this paper , the authors evaluated the antiviral effect, clinical outcomes, and safety of the respiratory syncytial virus (RSV) fusion inhibitor rilematovir in nonhospitalised RSV-infected adults.

TL;DR: CAEL-101 as mentioned in this paper is a monoclonal antibody that binds to amyloid fibrils and may facilitate their systemic removal, improve organ function, and patient survival.